百洋醫藥(301015.SZ)首日上市暴漲635% 再度臨停
格隆匯6月30日丨國內領先的健康品牌商業化平台百洋醫藥今日首日上市暴漲,盤中已幾度臨時停牌,截至目前暴漲635.08%報56.16元,再度停牌,最新市值295億元。該股暫成交12.26億元,換手率高達70.89%百洋醫藥主營業務分為三塊:品牌運營、批發配送、零售業務。其中,醫藥產品的品牌運營是公司的核心業務,目前主要運營品牌及產品包括迪巧系列、泌特系列、哈樂系列、武田系列等。招股書顯示,2018年和2019年,公司營收分別為36.52億元、48.48億元。2020年,儘管受到疫情影響,但公司仍實現營收58.79元,同比增長21.26%。同期,歸屬母公司淨利潤分別為2.58億元、2.10億元。2020年,其歸母淨利潤達到2.73億元,同比大增30%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.